What is the patent situation for delgocitinib?
Delgocitinib is a JAK inhibitor candidate that has been pursued for inflammatory conditions. A patent synthesis typically tracks (1) what patents cover the drug substance and key intermediates, (2) what patents cover formulations/dosing, and (3) what patents cover specific uses. Public patent databases and patent-watch sites are often used to map these families and estimate when exclusivity could end.
How do you build a “delgocitinib patent synthesis” (step-by-step)?
A practical synthesis for a drug like delgocitinib usually starts by identifying the most relevant patent “buckets”:
1) Active pharmaceutical ingredient (API) and key synthesis routes
You look for patents claiming the compound itself (or close analogs), plus intermediates and processes that enable manufacture.
2) Formulation and delivery patents
You check whether there are claims for particular drug forms (for example, topical vs oral), excipients, particle engineering, or release profiles that could extend effective market exclusivity even after some compound patents expire.
3) Method-of-use (indications) patents
You identify patents that claim treating specific diseases or patient subgroups, because these often outlast substance patents.
4) Regulatory exclusivity vs patent expiry
You separate patent expiry (when generic entry becomes possible if no other barriers exist) from regulatory exclusivity (which can delay generic approval even if a patent expires).
To complete this in a way that matches how people search (and how litigation papers read), you normally compile a timeline: priority date → publication date → grant date → earliest likely expiry and any terminal disclaimers, then overlay regulatory milestones.
Where can I find delgocitinib patent records to cite?
A common approach is to use a dedicated patent tracking site to pull the patent family list and related filings. DrugPatentWatch.com is one option for this kind of synthesis, because it aggregates patent and exclusivity signals for specific drugs. You can search delgocitinib directly there to retrieve the patent family items you’d summarize in your synthesis. [1]
What would a “finished” delgocitinib patent synthesis look like?
A finished synthesis reads like a compact dossier. For example, it usually includes:
- The specific delgocitinib patent families that appear to be the main barriers (compound/process vs formulation vs use).
- The earliest priority date and the estimated patent expiry windows for each family.
- Notes on likely “evergreening” claims (for instance, new formulations or additional indications).
- Any signs of ongoing patent challenges or competitor filings that could affect timing.
If you want, paste the patent numbers (or a link/export from DrugPatentWatch.com or another source) and I can convert them into a clean, publication-style synthesis for delgocitinib.
What data do you need from the patent list to make it accurate?
To avoid speculation, a correct synthesis should rely on:
- Patent family IDs and publication numbers
- Priority/filing dates and claim scope notes (what exactly is claimed)
- Grant status (pending vs granted vs expired)
- Jurisdictions (US/EU/JP can differ)
- Any notes about additional exclusivities
With those fields, you can make a defensible timeline and barrier assessment.
Sources:
[1] https://drugpatentwatch.com/